Fig. 2: Vaccine efficacy analysis. | Nature Communications

Fig. 2: Vaccine efficacy analysis.

From: Efficacy of the tetravalent protein COVID-19 vaccine, SCTV01E: a phase 3 double-blind, randomized, placebo-controlled trial

Fig. 2

Cumulative incidence for COVID-19 cases at 7 and 14 days post-injection of SCTV01E or placebo among population in PPE, were depicted in Panels (A) (symptomatic COVID-19 7 days post injection), B (all infections 7 days post injection), C (symptomatic COVID-19 14 days post injection), and D (all infections 14 days post injection).

Back to article page